What is the recommended dose, duration, and safety precautions for Tebonin (standardized Ginkgo biloba extract) in adult patients?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 23, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Tebonin (Ginkgo biloba Extract) Dosing and Safety Recommendations

Primary Recommendation

For adult patients with mild cognitive impairment or mild dementia, the recommended dose of standardized Ginkgo biloba extract (EGb 761) is 240 mg daily, divided into two 120 mg doses, with treatment duration of at least 24 weeks to achieve meaningful clinical benefit 1, 2, 3.

Dosing Algorithm

Standard Therapeutic Dosing

  • Dose: 240 mg/day (120 mg twice daily) of standardized extract EGb 761
  • Duration: Minimum 24 weeks for cognitive benefits; optimal results seen with 6 months or longer 4, 2, 5
  • Lower dose option: 120 mg/day may be considered, though evidence suggests 240 mg/day is more effective 4

Clinical Context

The evidence strongly supports 240 mg daily dosing. A 2025 meta-analysis of 782 patients with mild dementia demonstrated medium-to-large standardized effects on cognition, activities of daily living, global assessment, and quality of life with this dose 2. Studies using lower doses (60-120 mg/day) showed less consistent benefits 4.

Critical Safety Precautions

Perioperative Management

Discontinue Ginkgo biloba 2 weeks before any elective surgery 6, 7. This is a firm recommendation from the Society for Perioperative Assessment and Quality Improvement (SPAQI) 2021 consensus statement.

Mechanism of bleeding concern: Ginkgolide B displaces platelet-activating factor from binding sites, decreasing coagulation 6. While meta-analyses have not definitively shown increased bleeding risk, case reports exist and the theoretical concern warrants precaution 6, 7.

Drug Interactions to Monitor

Anticoagulants/Antiplatelets:

  • Warfarin: May alter INR; requires close monitoring 6
  • Antiplatelet drugs: Potential potentiation of effects 6, 7
  • Use with caution and monitor for bruising or bleeding

Other documented interactions 1, 8:

  • Monoamine oxidase inhibitors
  • Alprazolam
  • Haloperidol
  • Nifedipine
  • Omeprazole (weak CYP2C19 induction at doses >240 mg/day)
  • Midazolam (weak CYP3A4 inhibition at high doses)

Important Caveat

At the recommended dose of 240 mg/day of standardized EGb 761, clinically relevant pharmacokinetic interactions are minimal 8. The interaction risk increases with poorly standardized extracts or doses exceeding 240 mg/day.

Safety Profile

Adverse events: Frequency comparable to placebo in clinical trials 9, 4, 2. Minor side effects may include:

  • Gastrointestinal upset
  • Headache
  • Dizziness
  • Constipation
  • Allergic skin reactions 7

Mortality and cardiovascular safety: A large 5-year trial (2854 participants) found no difference in mortality (HR 0.94,95% CI 0.69-1.28) or stroke incidence (RR 1.12,95% CI 0.77-1.63) between Ginkgo and placebo groups 9.

Clinical Efficacy Evidence

Strongest evidence for:

  • Mild cognitive impairment and mild dementia 2, 3, 10
  • Cognitive domains: memory, processing speed, attention, executive function 3
  • Neuropsychiatric symptoms: depression and anxiety 3
  • Activities of daily living and quality of life 2

Insufficient evidence for:

  • Prevention of Alzheimer's disease progression 9
  • Acute ischemic stroke 7
  • Intermittent claudication 7
  • Tinnitus 7

Product Standardization

Critical point: Use only standardized extract EGb 761 or equivalent pharmaceutical-grade preparations. The evidence base specifically supports this standardized extract 1, 2, 3, 10. Poorly characterized supplements may have unpredictable effects and interaction profiles 8.

Common Pitfalls to Avoid

  1. Using non-standardized products: Evidence applies specifically to EGb 761; food supplements may not be equivalent
  2. Inadequate treatment duration: Benefits require minimum 24 weeks; shorter trials show inconsistent results
  3. Insufficient dosing: 240 mg/day shows superior efficacy to lower doses
  4. Failing to discontinue before surgery: Must stop 2 weeks preoperatively
  5. Ignoring warfarin interactions: Requires INR monitoring if co-prescribed

References

Research

Ginkgo biloba: indications, mechanisms, and safety.

The Psychiatric clinics of North America, 2013

Research

Ginkgo biloba extract EGb 761 is safe and effective in the treatment of mild dementia - a meta-analysis of patient subgroups in randomised controlled trials.

The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2025

Research

[Ginkgo biloba--effect, adverse events and drug interaction].

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2012

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.